UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported) ~~May~~ June 10, 2016

VACCINOGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

Maryland	000-54997	14-1997223
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

949 Fell Street, Baltimore, MD	21231
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (410) 387-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Section ~~1.01~~7 ~~Entry~~– ~~into~~Regulation aFD ~~Material Definitive Agreement.~~

~~Promissory~~Item ~~Note~~7.01 ~~Issued~~Regulation toFD ~~KLP Enterprises, LLC~~Disclosure.

OnVaccinogen ~~May~~has ~~10,~~filed ~~2016,~~a ~~Vaccinogen,~~new patent application related to methods ~~Inc.~~of ~~(the~~characterizing ~~“Company”)~~antigenic ~~issued~~determinants anwhich ~~Unsecured~~broadly ~~Promissory~~define ~~Note~~adenocarcinomas (with the ~~“Note”~~ guidance of human monoclonal antibodies (HuMabs) reactive to ~~KLP~~such ~~Enterprises, LLC~~epitopes. (One aspect involves characterization of the ~~“Lender”)~~critical inantigenic determinants (epitopes) with a ~~principal~~high ~~amount~~degree of ~~One~~inter- ~~Million~~and ~~Six~~intra-tumoral ~~Hundred~~incidence ~~Thousand~~across ~~Dollars~~a ~~($1,600,000),~~broad ~~bearing~~range ~~interest~~of adenocarcinomas. The patent application also atrelates ato ~~rate~~the physical recapitulation of ~~nine~~the ~~percent~~epitopes, ~~(9%)~~generating ~~per~~a ~~annum~~cohort of specific peptides, ~~and~~which ~~maturing~~may onbe ~~June~~useful ~~30,~~for ~~2016~~vaccinating humans ~~(the~~against ~~“Maturity~~a ~~Date”)~~wide range of adenocarcinomas using a limited number of homogeneous tumor antigens.

The Note provides the Lender the right, at any time before the Maturity Date, to elect to convert part or all of the outstanding principal and any interest due and payable under the Note into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a rate of $2.00 per share by providing the Company written notice of such election. The Company’s obligation to issue Common Stock pursuant to the Note is conditioned upon the Company and the Lender entering into a mutually agreeable subscription agreement prior to such issuance, substantially in the form attached to the Note.

This description of the Note does not purport to be complete and is qualified in its entirety by reference to the Note attached as an exhibit to this Current Report on Form 8-K and incorporated herein by reference.SIGNATURES

~~Section~~Pursuant 9to –the ~~Financial~~requirements ~~Statements~~of ~~and~~the ~~Exhibits~~Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 9.01 Financial Statements and Exhibits.

	VACCINOGEN, INC.

Date: June 10, 2016	By:	/s/ Andrew L. Tussing
		Andrew L. Tussing
		Chairman and Chief Executive Officer

~~(d) Exhibits.~~3

Exhibit
Number		Description
10.1		$1,600,000 Unsecured Promissory Note dated May 10, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VACCINOGEN, INC.
Date: May 13, 2016	By:	/s/ Andrew L. Tussing
		Andrew L. Tussing
		Chairman and Chief Executive Officer

Exhibit Index

Exhibit
Number		Description
10.1		$1,600,000 Unsecured Promissory Note dated May 10, 2016

Filing Compare · VACCINOGEN INC